Whole-genome analysis informs breast cancer response to aromatase inhibition.

PubWeight™: 8.03‹?› | Rank: Top 0.1%

🔗 View Article (PMC 3383766)

Published in Nature on June 10, 2012

Authors

Matthew J Ellis1, Li Ding, Dong Shen, Jingqin Luo, Vera J Suman, John W Wallis, Brian A Van Tine, Jeremy Hoog, Reece J Goiffon, Theodore C Goldstein, Sam Ng, Li Lin, Robert Crowder, Jacqueline Snider, Karla Ballman, Jason Weber, Ken Chen, Daniel C Koboldt, Cyriac Kandoth, William S Schierding, Joshua F McMichael, Christopher A Miller, Charles Lu, Christopher C Harris, Michael D McLellan, Michael C Wendl, Katherine DeSchryver, D Craig Allred, Laura Esserman, Gary Unzeitig, Julie Margenthaler, G V Babiera, P Kelly Marcom, J M Guenther, Marilyn Leitch, Kelly Hunt, John Olson, Yu Tao, Christopher A Maher, Lucinda L Fulton, Robert S Fulton, Michelle Harrison, Ben Oberkfell, Feiyu Du, Ryan Demeter, Tammi L Vickery, Adnan Elhammali, Helen Piwnica-Worms, Sandra McDonald, Mark Watson, David J Dooling, David Ota, Li-Wei Chang, Ron Bose, Timothy J Ley, David Piwnica-Worms, Joshua M Stuart, Richard K Wilson, Elaine R Mardis

Author Affiliations

1: Department of Internal Medicine, Division of Oncology, Washington University, St Louis, Missouri 63110, USA.

Associated clinical trials:

Exemestane, Letrozole, or Anastrozole in Treating Postmenopausal Women Who Are Undergoing Surgery for Stage II or Stage III Breast Cancer | NCT00265759

Neoadjuvant Letrozole in Treating Postmenopausal Women With Estrogen-Receptor Positive and/or Progesterone-Receptor Positive Stage II, Stage IIIA, or Stage IIIB Breast Cancer | NCT00084396

Articles citing this

(truncated to the top 100)

Cancer genome landscapes. Science (2013) 25.33

Mutational landscape and significance across 12 major cancer types. Nature (2013) 14.91

Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013. Ann Oncol (2013) 9.68

Activating HER2 mutations in HER2 gene amplification negative breast cancer. Cancer Discov (2012) 4.72

Clonal evolution in breast cancer revealed by single nucleus genome sequencing. Nature (2014) 4.13

Activating ESR1 mutations in hormone-resistant metastatic breast cancer. Nat Genet (2013) 3.96

Endocrine-therapy-resistant ESR1 variants revealed by genomic characterization of breast-cancer-derived xenografts. Cell Rep (2013) 3.85

Proteomic and bioinformatic analysis of mammalian SWI/SNF complexes identifies extensive roles in human malignancy. Nat Genet (2013) 3.51

How many etiological subtypes of breast cancer: two, three, four, or more? J Natl Cancer Inst (2014) 3.43

Concordance between CYP2D6 genotypes obtained from tumor-derived and germline DNA. J Natl Cancer Inst (2013) 3.35

Evolution of the cancer genome. Nat Rev Genet (2012) 3.24

Landscape of somatic mutations in 560 breast cancer whole-genome sequences. Nature (2016) 3.05

Addressing overdiagnosis and overtreatment in cancer: a prescription for change. Lancet Oncol (2014) 3.04

Emergence of constitutively active estrogen receptor-α mutations in pretreated advanced estrogen receptor-positive breast cancer. Clin Cancer Res (2014) 2.92

Dynamics of genomic clones in breast cancer patient xenografts at single-cell resolution. Nature (2014) 2.85

Evolutionary dynamics of cancer in response to targeted combination therapy. Elife (2013) 2.76

Cancer heterogeneity: implications for targeted therapeutics. Br J Cancer (2013) 2.56

The spliceosome as a target of novel antitumour drugs. Nat Rev Drug Discov (2012) 2.51

Emerging patterns of somatic mutations in cancer. Nat Rev Genet (2013) 2.50

Coming of age: ten years of next-generation sequencing technologies. Nat Rev Genet (2016) 2.48

Recurrent mutations at codon 625 of the splicing factor SF3B1 in uveal melanoma. Nat Genet (2013) 2.20

Visualizing multidimensional cancer genomics data. Genome Med (2013) 2.19

A triple helix stabilizes the 3' ends of long noncoding RNAs that lack poly(A) tails. Genes Dev (2012) 2.13

IntOGen-mutations identifies cancer drivers across tumor types. Nat Methods (2013) 2.10

An international effort towards developing standards for best practices in analysis, interpretation and reporting of clinical genome sequencing results in the CLARITY Challenge. Genome Biol (2014) 1.95

Whole-genome sequencing provides new insights into the clonal architecture of Barrett's esophagus and esophageal adenocarcinoma. Nat Genet (2015) 1.89

H3K4 mono- and di-methyltransferase MLL4 is required for enhancer activation during cell differentiation. Elife (2013) 1.81

Subclonal diversification of primary breast cancer revealed by multiregion sequencing. Nat Med (2015) 1.74

Correlative Analysis of Genetic Alterations and Everolimus Benefit in Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: Results From BOLERO-2. J Clin Oncol (2015) 1.73

The genomic landscape of breast cancer as a therapeutic roadmap. Cancer Discov (2013) 1.71

Prognostic and predictive value of PDL1 expression in breast cancer. Oncotarget (2015) 1.62

High expression of lncRNA MALAT1 suggests a biomarker of poor prognosis in colorectal cancer. Int J Clin Exp Pathol (2014) 1.62

Comparison of clinical targeted next-generation sequence data from formalin-fixed and fresh-frozen tissue specimens. J Mol Diagn (2013) 1.59

Ischemia in tumors induces early and sustained phosphorylation changes in stress kinase pathways but does not affect global protein levels. Mol Cell Proteomics (2014) 1.59

Emerging targeted agents in metastatic breast cancer. Nat Rev Clin Oncol (2013) 1.59

Concordance of genomic alterations between primary and recurrent breast cancer. Mol Cancer Ther (2014) 1.57

Cancer genome-sequencing study design. Nat Rev Genet (2013) 1.55

Obesity and cancer--mechanisms underlying tumour progression and recurrence. Nat Rev Endocrinol (2014) 1.51

Tumor Evolution in Two Patients with Basal-like Breast Cancer: A Retrospective Genomics Study of Multiple Metastases. PLoS Med (2016) 1.48

Mutational landscape of aggressive cutaneous squamous cell carcinoma. Clin Cancer Res (2014) 1.47

A new genome-driven integrated classification of breast cancer and its implications. EMBO J (2013) 1.47

Patient-derived xenograft models of breast cancer and their predictive power. Breast Cancer Res (2015) 1.43

Recurrent and functional regulatory mutations in breast cancer. Nature (2017) 1.39

Genome-driven integrated classification of breast cancer validated in over 7,500 samples. Genome Biol (2014) 1.38

Stand up to cancer phase Ib study of pan-phosphoinositide-3-kinase inhibitor buparlisib with letrozole in estrogen receptor-positive/human epidermal growth factor receptor 2-negative metastatic breast cancer. J Clin Oncol (2014) 1.38

Somatic mutation profiling and associations with prognosis and trastuzumab benefit in early breast cancer. J Natl Cancer Inst (2013) 1.38

Genome evolution during progression to breast cancer. Genome Res (2013) 1.37

The genomic landscape of small intestine neuroendocrine tumors. J Clin Invest (2013) 1.37

Serial monitoring of circulating tumor DNA in patients with primary breast cancer for detection of occult metastatic disease. EMBO Mol Med (2015) 1.37

Circulating tumour cells and cell-free DNA as tools for managing breast cancer. Nat Rev Clin Oncol (2013) 1.33

Integrated analysis of germline and somatic variants in ovarian cancer. Nat Commun (2014) 1.31

Differentiation of mammary tumors and reduction in metastasis upon Malat1 lncRNA loss. Genes Dev (2015) 1.27

Functional Genomic Landscape of Human Breast Cancer Drivers, Vulnerabilities, and Resistance. Cell (2016) 1.26

The need for complex 3D culture models to unravel novel pathways and identify accurate biomarkers in breast cancer. Adv Drug Deliv Rev (2014) 1.25

Clinical management of breast cancer heterogeneity. Nat Rev Clin Oncol (2015) 1.22

Characterization of the genomic features and expressed fusion genes in micropapillary carcinomas of the breast. J Pathol (2014) 1.19

Enhancer malfunction in cancer. Mol Cell (2014) 1.19

JARID1B is a luminal lineage-driving oncogene in breast cancer. Cancer Cell (2014) 1.19

Navigating cancer network attractors for tumor-specific therapy. Nat Biotechnol (2012) 1.18

Performance of common analysis methods for detecting low-frequency single nucleotide variants in targeted next-generation sequence data. J Mol Diagn (2013) 1.17

Targeted biomarker profiling of matched primary and metastatic estrogen receptor positive breast cancers. PLoS One (2014) 1.17

Genome-wide reprogramming of the chromatin landscape underlies endocrine therapy resistance in breast cancer. Proc Natl Acad Sci U S A (2013) 1.16

Luminal breast cancer: from biology to treatment. Nat Rev Clin Oncol (2013) 1.16

The somatic mutation profiles of 2,433 breast cancers refines their genomic and transcriptomic landscapes. Nat Commun (2016) 1.15

The AURORA initiative for metastatic breast cancer. Br J Cancer (2014) 1.15

What are we learning from the cancer genome? Nat Rev Clin Oncol (2012) 1.13

The search for ESR1 mutations in breast cancer. Nat Genet (2013) 1.13

Long noncoding RNAs: Re-writing dogmas of RNA processing and stability. Biochim Biophys Acta (2015) 1.08

The RUNX1 transcription factor is expressed in serous epithelial ovarian carcinoma and contributes to cell proliferation, migration and invasion. Cell Cycle (2013) 1.08

Invasive lobular carcinoma of the breast: morphology, biomarkers and 'omics. Breast Cancer Res (2015) 1.08

SF3B1 mutations constitute a novel therapeutic target in breast cancer. J Pathol (2014) 1.07

The molecular diversity of Luminal A breast tumors. Breast Cancer Res Treat (2013) 1.07

Detection of structural DNA variation from next generation sequencing data: a review of informatic approaches. Cancer Genet (2013) 1.06

Induction of Wnt-inducible signaling protein-1 correlates with invasive breast cancer oncogenesis and reduced type 1 cell-mediated cytotoxic immunity: a retrospective study. PLoS Comput Biol (2014) 1.05

Advances in Breast Cancer - Looking Back over the Year. Geburtshilfe Frauenheilkd (2012) 1.05

Next generation sequencing in cancer research and clinical application. Biol Proced Online (2013) 1.05

Mechanisms of genome instability induced by RNA-processing defects. Trends Genet (2014) 1.04

The mutational landscape of chromatin regulatory factors across 4,623 tumor samples. Genome Biol (2013) 1.03

Functional analysis of non-hotspot AKT1 mutants found in human breast cancers identifies novel driver mutations: implications for personalized medicine. Oncotarget (2013) 1.03

NeoPalAna: Neoadjuvant palbociclib, a cyclin-dependent kinase 4/6 inhibitor, and anastrozole for clinical stage 2 or 3 estrogen receptor positive breast cancer. Clin Cancer Res (2017) 1.03

Somatic neurofibromatosis type 1 (NF1) inactivation characterizes NF1-associated pilocytic astrocytoma. Genome Res (2012) 1.02

Posttranslational modifications of RUNX1 as potential anticancer targets. Oncogene (2014) 1.00

Lack of SF3B1 R625 mutations in cutaneous melanoma. Diagn Pathol (2013) 1.00

Models of signalling networks - what cell biologists can gain from them and give to them. J Cell Sci (2013) 0.99

PIK3R1 underexpression is an independent prognostic marker in breast cancer. BMC Cancer (2013) 0.99

MuPIT interactive: webserver for mapping variant positions to annotated, interactive 3D structures. Hum Genet (2013) 0.99

U2AF35(S34F) Promotes Transformation by Directing Aberrant ATG7 Pre-mRNA 3' End Formation. Mol Cell (2016) 0.98

Personal genomes, quantitative dynamic omics and personalized medicine. Quant Biol (2013) 0.98

Expression of RUNX1 correlates with poor patient prognosis in triple negative breast cancer. PLoS One (2014) 0.98

Coherence between cellular responses and in vitro splicing inhibition for the anti-tumor drug pladienolide B and its analogs. J Biol Chem (2013) 0.97

Kinesin family deregulation coordinated by bromodomain protein ANCCA and histone methyltransferase MLL for breast cancer cell growth, survival, and tamoxifen resistance. Mol Cancer Res (2014) 0.96

RUNX1, a transcription factor mutated in breast cancer, controls the fate of ER-positive mammary luminal cells. Elife (2014) 0.96

Intracellular calcium regulates nonsense-mediated mRNA decay. Nat Med (2014) 0.96

A Phase I Trial of BKM120 (Buparlisib) in Combination with Fulvestrant in Postmenopausal Women with Estrogen Receptor-Positive Metastatic Breast Cancer. Clin Cancer Res (2015) 0.96

The Drosophila ortholog of MLL3 and MLL4, trithorax related, functions as a negative regulator of tissue growth. Mol Cell Biol (2013) 0.96

p53 accumulation is a strong predictor of recurrence in estrogen receptor-positive breast cancer patients treated with aromatase inhibitors. Cancer Sci (2013) 0.95

Next-generation sequencing in breast cancer: first take home messages. Curr Opin Oncol (2012) 0.95

Identifying potential cancer driver genes by genomic data integration. Sci Rep (2013) 0.95

Fine mapping of breast cancer genome-wide association studies loci in women of African ancestry identifies novel susceptibility markers. Carcinogenesis (2013) 0.95

Genomic, prognostic, and cell-signaling advances in uveal melanoma. Am Soc Clin Oncol Educ Book (2013) 0.94

Articles cited by this

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med (2004) 71.08

Circos: an information aesthetic for comparative genomics. Genome Res (2009) 40.02

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

High frequency of mutations of the PIK3CA gene in human cancers. Science (2004) 27.94

A comprehensive catalogue of somatic mutations from a human cancer genome. Nature (2009) 24.27

BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41

A small-cell lung cancer genome with complex signatures of tobacco exposure. Nature (2009) 18.39

Mitogen-activated protein kinase pathways mediated by ERK, JNK, and p38 protein kinases. Science (2002) 14.50

SF3B1 and other novel cancer genes in chronic lymphocytic leukemia. N Engl J Med (2011) 11.07

Diverse somatic mutation patterns and pathway alterations in human cancers. Nature (2010) 10.83

The mutation spectrum revealed by paired genome sequences from a lung cancer patient. Nature (2010) 10.04

Signal integration by JNK and p38 MAPK pathways in cancer development. Nat Rev Cancer (2009) 9.33

The nuclear-retained noncoding RNA MALAT1 regulates alternative splicing by modulating SR splicing factor phosphorylation. Mol Cell (2010) 8.66

Inference of patient-specific pathway activities from multi-dimensional cancer genomics data using PARADIGM. Bioinformatics (2010) 8.44

Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts. N Engl J Med (2011) 7.89

SomaticSniper: identification of somatic point mutations in whole genome sequencing data. Bioinformatics (2011) 5.62

E-cadherin is a tumour/invasion suppressor gene mutated in human lobular breast cancers. EMBO J (1995) 4.55

Mutation of GATA3 in human breast tumors. Oncogene (2004) 3.92

High-resolution characterization of a hepatocellular carcinoma genome. Nat Genet (2011) 3.86

Outcome prediction for estrogen receptor-positive breast cancer based on postneoadjuvant endocrine therapy tumor characteristics. J Natl Cancer Inst (2008) 3.21

Structural rearrangement of the retinoblastoma gene in human breast carcinoma. Science (1988) 2.83

Randomized phase II neoadjuvant comparison between letrozole, anastrozole, and exemestane for postmenopausal women with estrogen receptor-rich stage 2 to 3 breast cancer: clinical and biomarker outcomes and predictive value of the baseline PAM50-based intrinsic subtype--ACOSOG Z1031. J Clin Oncol (2011) 2.71

MALAT-1: a long non-coding RNA and its important 3' end functional motif in colorectal cancer metastasis. Int J Oncol (2011) 2.59

Estrogen expands breast cancer stem-like cells through paracrine FGF/Tbx3 signaling. Proc Natl Acad Sci U S A (2010) 2.46

MEK kinases are regulated by EGF and selectively interact with Rac/Cdc42. EMBO J (1997) 2.38

Mammary development meets cancer genomics. Nat Med (2009) 2.04

p27/Kip1 mutation found in breast cancer. Cancer Res (1996) 1.94

Genome-wide analysis of estrogen receptor alpha DNA binding and tethering mechanisms identifies Runx1 as a novel tethering factor in receptor-mediated transcriptional activation. Mol Cell Biol (2010) 1.75

Evidence that p53 behaves as a tumour suppressor gene in sporadic breast tumours. Oncogene (1990) 1.70

JNK1 phosphorylation of SCG10 determines microtubule dynamics and axodendritic length. J Cell Biol (2006) 1.69

The May-Hegglin anomaly gene MYH9 is a negative regulator of platelet biogenesis modulated by the Rho-ROCK pathway. Blood (2007) 1.64

Phosphatidyl-inositol-3-kinase alpha catalytic subunit mutation and response to neoadjuvant endocrine therapy for estrogen receptor positive breast cancer. Breast Cancer Res Treat (2010) 1.60

Improved surgical outcomes for breast cancer patients receiving neoadjuvant aromatase inhibitor therapy: results from a multicenter phase II trial. J Am Coll Surg (2009) 1.46

PathScan: a tool for discerning mutational significance in groups of putative cancer genes. Bioinformatics (2011) 1.46

DNA sequence of the translocation breakpoints in undifferentiated embryonal sarcoma arising in mesenchymal hamartoma of the liver harboring the t(11;19)(q11;q13.4) translocation. Genes Chromosomes Cancer (2007) 1.40

Functional and physical interactions between AML1 proteins and an ETS protein, MEF: implications for the pathogenesis of t(8;21)-positive leukemias. Mol Cell Biol (1999) 1.40

Molecular mechanisms of autosomal recessive hypercholesterolemia. Hum Mol Genet (2002) 1.33

Phosphorylation of SCG10/stathmin-2 determines multipolar stage exit and neuronal migration rate. Nat Neurosci (2011) 1.29

Antifibrotic effect of tamoxifen in a model of progressive renal disease. J Am Soc Nephrol (2011) 1.20

Somatic mutations of the mixed-lineage leukemia 3 (MLL3) gene in primary breast cancers. Pathol Oncol Res (2010) 1.18

Neoadjuvant endocrine therapy in primary breast cancer: indications and use as a research tool. Br J Cancer (2010) 1.13

Non-muscle myosin heavy chain (MYH9): a new partner fused to ALK in anaplastic large cell lymphoma. Genes Chromosomes Cancer (2003) 1.13

Potentiation of apoptosis by low dose stress stimuli in cells expressing activated MEK kinase 1. Oncogene (1997) 1.07

Articles by these authors

Initial sequencing and comparative analysis of the mouse genome. Nature (2002) 96.15

A second generation human haplotype map of over 3.1 million SNPs. Nature (2007) 85.39

Identification and analysis of functional elements in 1% of the human genome by the ENCODE pilot project. Nature (2007) 75.09

An obesity-associated gut microbiome with increased capacity for energy harvest. Nature (2006) 44.35

Evolutionarily conserved elements in vertebrate, insect, worm, and yeast genomes. Genome Res (2005) 44.08

Integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR, and NF1. Cancer Cell (2010) 39.09

DNA sequencing of a cytogenetically normal acute myeloid leukaemia genome. Nature (2008) 38.13

The genomic landscapes of human breast and colorectal cancers. Science (2007) 38.12

Trastuzumab plus adjuvant chemotherapy for operable HER2-positive breast cancer. N Engl J Med (2005) 33.60

Recurring mutations found by sequencing an acute myeloid leukemia genome. N Engl J Med (2009) 33.09

Whole-genome sequencing and variant discovery in C. elegans. Nat Methods (2008) 31.92

Mapping and sequencing of structural variation from eight human genomes. Nature (2008) 30.28

Somatic mutations affect key pathways in lung adenocarcinoma. Nature (2008) 30.02

American Society of Clinical Oncology/College of American Pathologists guideline recommendations for human epidermal growth factor receptor 2 testing in breast cancer. J Clin Oncol (2006) 25.12

Human papillomavirus and survival of patients with oropharyngeal cancer. N Engl J Med (2010) 22.74

International network of cancer genome projects. Nature (2010) 20.35

Genomic and epigenomic landscapes of adult de novo acute myeloid leukemia. N Engl J Med (2013) 19.87

Genome remodelling in a basal-like breast cancer metastasis and xenograft. Nature (2010) 19.68

A comparison of laparoscopically assisted and open colectomy for colon cancer. N Engl J Med (2004) 19.45

The B73 maize genome: complexity, diversity, and dynamics. Science (2009) 18.73

BreakDancer: an algorithm for high-resolution mapping of genomic structural variation. Nat Methods (2009) 18.41

Evolution of genes and genomes on the Drosophila phylogeny. Nature (2007) 18.01

Genome-wide detection and characterization of positive selection in human populations. Nature (2007) 17.27